Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort.
SABCS 2018
Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.
Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
Researchers find that surgical decision making is often driven by factors beyond extent of disease.
Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer
The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.
Rates of Adverse Events Similar Regardless of IMRT Boost Type
The rates of adverse events seen across dose schedule type for patients who underwent IMRT were roughly similar.
TAILORx Shows Black Women With Breast Cancer Have Worse Clinical Outcomes
Black women with the most common type of breast cancer had worse clinical outcomes compared with white women, despite receiving similar systemic therapy.
Partial-Breast Irradiation Not Equal to Whole-Breast Irradiation in Early-Stage Breast Cancer
Partial-breast irradiation failed to meet protocol-defined measures for equivalence.
Alpelisib Plus Fulvestrant Continues to Show Improved PFS in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer
Alpelisib plus fulvestrant consistently resulted in prolonged PFS among patients with HR-positive, HER2-negative advanced breast cancer who also had PIK3CA mutations.
High CTC Count Favors Chemotherapy in First-Line ER+, HER2- Metastatic Breast Cancer
CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.
Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
The extension of adjuvant anastrozole to 10 years of treatment showed higher rates of DFS and distant DFS, but did not improve overall survival.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in SABCS 2018
Loading... 
Loading...